Lusutrombopag

Phase 3

Shionogi (SGIOY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Chronic Liver Disease

CCRNLAENNEC (Human Placenta Hydrolysate) IV

Phase 3

CCRNLAENNEC (Human Placenta Hydrolysate)

Phase 2

View Full Landscape

Drug Information

Target Indication

Chronic Liver Disease

Clinical Trial

NCT02389621

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA2/18/2019

Mulpleo (previously Lusutrombopag Shionogi)

Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SGIOY

Shionogi

Healthcare•North America•NASDAQ

Related Pipeline

Ospemifene 60Mg Oral TabletPhase 3

Atrophy

Oral Glycopyrrolate LiquidPhase 3

Cerebral Palsy

Ospemifene (Dose 1)Phase 3

Atrophy

Ospemifene 30 mgPhase 3

Atrophy

MeropenemPhase 3

Healthcare-associated Pneumonia (HCAP)

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts